| 查看: 342 | 回复: 0 | |||
[交流]
Vivitrol和抑郁:病例报告及文献复习
|
|
The introduction of a long-acting depot formulation of naltrexone (Vivitrol), FDA approved for the treatment of alcohol and opioid dependence in 2006 and 2010, respectively, has raised safety concerns including: (1) risk of development or exacerbation of depressive symptoms during treatment; and (2) increased risk of opioid overdose after treatment cessation. The concern that treatment with long-acting naltrexone may lead to depressive symptoms has a plausible theoretical basis given the medication’s blockade of μ-opioid receptors, which, when activated, lead to positive mood states. Risk of depression and suicidality are listed as potential adverse reactions in the manufacturer’s insert and are commonly relayed to patients during informed consent for treatment (http://www.vivitrol.com/About/Safety). However, these concerns may not be substantiated. Given that depression is commonly comorbid with alcohol and opioid dependence, concerns about the exacerbation of depression could prevent many individuals from receiving beneficial treatment as more evidence emerges supporting the efficacy of depot naltrexone. A recent multisite randomized trial found that opioid-dependent subjects receiving long-acting naltrexone were far more likely to remain abstinent over 6 months of treatment (median of 90% abstinent weeks for naltrexone group vs. 35% for placebo group). In this paper, we review the existing literature on the effects of short-acting and long-acting naltrexone on mood as well as effects on preexisting depressive disorders, with the aim of assisting clinicians in selecting appropriate patients for treatment with this medication. provide:www.tianyuan520.com |
» 本帖附件资源列表
-
欢迎监督和反馈:小木虫仅提供交流平台,不对该内容负责。
本内容由用户自主发布,如果其内容涉及到知识产权问题,其责任在于用户本人,如对版权有异议,请联系邮箱:xiaomuchong@tal.com - 附件 1 : 00132576-201409000-00007.pdf
2014-09-30 15:38:12, 99.98 K
» 猜你喜欢
中了面上,感谢小本虫,这是我唯一的获取信息渠道。
已经有22人回复
26申博求推荐,生物医学工程/计算机视觉/医学图像目标检测与分割
已经有3人回复
神经系统和精神疾病论文润色/翻译怎么收费?
已经有279人回复
【CSC招生】荷兰莱顿大学医学中心LKEB图像处理实验室 招收2026年CSC博士生多名
已经有12人回复
审稿快的SCI医学期刊推荐
已经有0人回复
审稿快的SCI医学期刊
已经有0人回复
西安交通大学生命学院智能化诊疗装备研究中心2026年博士生招生
已经有9人回复
湖南工业大学-生物医学工程-招收调剂
已经有0人回复












回复此楼